



March 15, 2023

**Mylan Institutional LLC
Notice Regarding Ultiva® National Drug Code Numbers
And Impact on 340B Virtual Inventory Management**

Mylan Institutional LLC, a Viatriis company (“Viatriis”) has asked the Office of Pharmacy Affairs (“OPA”) to post this notice on OPA’s public website to notify 340B covered entities that the national drug code (NDC) numbers for Ultiva® (remifentanil hydrochloride) for Injection, for intravenous use (“ULTIVA”) are being transitioned to new NDCs as follows:

Description	OLD/EXISTING NDC	NEW/REPLACEMENT NDC
ULTIVA 1mg LYO 10PK	67457-198-03	72078-034-01
ULTIVA 2mg LYO 10PK	67457-198-05	72078-035-02
ULTIVA 5mg LYO 10PK	67457-198-10	72078-036-05

Viatriis will sell its remaining inventory of each old NDC until it is exhausted, at which point it will begin distributing the corresponding new NDC. Viatriis or your distributor will communicate further information regarding the availability of each new NDC.

The new NDCs do not signify any change in product form, strength, or composition. Viatriis will treat each new NDC the same as the corresponding old NDC with respect to pricing and purchasing from Viatriis under the 340B program. Because each new ULTIVA NDC represents the same product with the same 340B ceiling price as the corresponding old NDC, Viatriis will permit an eligible 340B covered entity using a compliant 340B inventory replenishment model to count accumulations of each old NDC toward replenishment of equal quantities of each corresponding new NDC.

Any questions regarding this notice can be sent to Viatriis Customer Service at Customer.Service@Viatriis.com.